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Abstract
Background: Chagas disease induced by Trypanosoma cruzi (T. cruzi) infection is a major cause of mortality and morbidity
affecting the cardiovascular system for which presently available therapies are largely inadequate. Transforming Growth
Factor beta (TGFß) has been involved in several regulatory steps of T. cruzi invasion and in host tissue fibrosis. GW788388 is
a new TGFß type I and type II receptor kinase inhibitor that can be orally administered. In the present work, we studied its
effects in vivo during the acute phase of experimental Chagas disease.
Methodology/Principal Findings: Male Swiss mice were infected intraperitoneally with 10
4 trypomastigotes of T. cruzi (Y
strain) and evaluated clinically. We found that this compound given once 3 days post infection (dpi) significantly decreased
parasitemia, increased survival, improved cardiac electrical conduction as measured by PR interval in electrocardiography,
and restored connexin43 expression. We could further show that cardiac fibrosis development, evaluated by collagen type I
and fibronectin expression, could be inhibited by this compound. Interestingly, we further demonstrated that
administration of GW788388 at the end of the acute phase (20 dpi) still significantly increased survival and decreased
cardiac fibrosis (evaluated by Masson’s trichrome staining and collagen type I expression), in a stage when parasite growth
is no more central to this event.
Conclusion/Significance: This work confirms that inhibition of TGFß signaling pathway can be considered as a potential
alternative strategy for the treatment of the symptomatic cardiomyopathy found in the acute and chronic phases of Chagas
disease.
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Introduction
Chagas disease, caused by the intracellular kinetoplastid
parasite Trypanosoma cruzi, is a widely spread distributed debilitat-
ing human illness, affecting 10–12 million people in Central and
South America. It is a major cause of mortality and morbidity,
killing 15,000 persons each year [1,2]. Chagas disease presents an
acute phase of infection that is characterized by mild clinical
symptoms (fever and malaise) and high parasitemia, but is often
unmarked. Due to a potent specific immune response which
control parasitemia, patients usually attain the indeterminate stage
of the infection, with low-level of parasite persistence that can last
from 10 to 40 years. About one in three infected individuals
develops the symptomatic chronic stage of infection, which is
characterized mainly by myocardiopathy or/and intestinal mega-
syndrome. A century has passed since the discovery of Chagas
disease and the development of an efficient drug is still a challenge.
As other neglected diseases, it has not received much attention of
the pharmaceutical industry and present available therapies are
insufficient [3]. Nifurtimox and benznidazole, the only two
trypanocide drugs available, have toxic side effects, are not
effective for all parasite strains and the effect in human chronic
phase is still under clinical trial [4]. Moreover, no therapeutic
approach targeting Chagas disease heart fibrosis is presently
available.
Transforming Growth Factor ß1 (TGFß1) is the prototypic
member of a family of polypeptide growth and differentiation
factors that play a great variety of biological roles in such diverse
www.plosntds.org 1 June 2012 | Volume 6 | Issue 6 | e1696processes as inflammation, fibrosis, immune suppression, cell
proliferation, cell differentiation, and cell death [5,6]. TGFß is also
involved in many direct and indirect interactions between
infectious agents and their hosts [7]. Several studies have
demonstrated that TGFß plays a major role in the establishment
and pathogenesis of T. cruzi infection (reviewed in [8]). Moreover,
significantly higher circulating levels of TGFß1 have been
observed in patients with Chagas disease cardiomyopathy [9]
and in a culture system of cardiomyocytes infected by T. cruzi [10].
In order to establish its biological functions, TGFß must be
activated into a mature form mainly by proteases, allowing its
interaction with a specific transmembrane receptor called TGFß
receptor-II (TßRII), which phosphorylates and stimulates the
serine/threonine kinase activity of TßRI, also called activin
receptor-like kinase 5 (ALK5). Upon activation, ALK5 phosphor-
ylates the cytoplasmic signaling proteins Smad-2 and -3, which
then associate with Smad-4, translocate into the nucleus as a
multiprotein complex, and stimulate the transcription of TGFß-
responsive genes, thereby inducing specific biological responses.
We have recently described that the ALK5 inhibitor, 4-(5-
benzo[1,3]dioxol-5-yl-4- pyridin-2-yl-1H-imidazol-2-yl)-benzamide
(SB431542) reduces the infection of cardiomyocytes by T. cruzi in
vitro [11] and we could further show that it also inhibited T. cruzi
infection in vivo and prevented heart damage in a mouse model [12].
This work therefore clearly demonstrated that blocking the TGFß
signaling pathway could be a new therapeutical approach in the
treatmentofChagasdiseaseheartpathology.Howeverthelimitation
ofthiscompoundwasthepreclusiontooraladministrationandsome
toxic effects. To reinforce the prove of concept, the aim of the
present work wastherefore to test, inthe sameparasite-mousemodel
of experimental Chagas disease, another inhibitor of the TGFß
signaling pathway, 4-(4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl] pyridin-2-
yl)-N-(tetrahydro-2Hpyran-4-yl) benzamide (GW788388) which can
be orally administered and that has an improved pharmacokinetic
profile [13,14]. We found that GW788388 added 3-day post
infection (dpi) decreased parasitemia, increased survival, prevented
heart damage, and decreased heart fibrosis. Very importantly, we
also demonstrated here for the first time that when added after the
end of the intense parasite growth and consequent metabolic shock
phase at 20 dpi, GW788388 could still decrease mortality and heart
fibrosis.
Methods
Parasites
Bloodstream trypomastigotes of the Y strain were used and
harvested by heart puncture from T. cruzi-infected Swiss mice at
the parasitemia peak, as described previously [15].
Ethics statement
Mice were housed for at least one week before parasite infection
at the Animal Experimentation Section at the Laboratory of
Innovations in Therapies, Education and Bioproducts-IOC/
FIOCRUZ under environmental factors and sanitation according
to ‘‘Guide for the Care and Use of Laboratory Animals’’. Animal
studies adhered to the International guidelines (National Research
Council. 1996, National Academy press, Washington, DC). This
project was approved by the FIOCRUZ Committee of Ethics in
Research (protocol number 028/09).
In vivo infection. Male Swiss mice (age 6–8 weeks, weight
18–20 g) were obtained from the animal facilities of CECAL
(FIOCRUZ, Rio de Janeiro, Brazil). Infection was performed by
intraperitoneal (IP) injection of 10
4 bloodstream trypomastigotes.
Age-matched non-infected mice were maintained under identical
conditions.
Experimental groups. The animals were divided into the
following groups: non-infected (NI), infected and untreated (Y
DMSO), infected and treated with 3 mg/kg GW783388 (Y
GW788388). Ten mice from each group were used for analysis
at each different dpi and 5 independent experiments were
performed.
Drug and treatment. The compound GW783388 (Glaxo-
Smithkline, France) or vehicle dilution buffer (4% DMSO, 96%
[0.5% Hydroxypropylmethylcellulose (HPMC), 5% Tween 20,
20% HCl 1 M in NaH2PO4 0.1 M]) was used for oral
administration. Mice received GW788388 at 3 mg/kg at 3 dpi
or 20 dpi by gavage in a single administration (0.2 mL). The
control group received vehicle buffer using the same schedule.
Survival rates and parasitemia. Parasitemia was individ-
ually checked by direct microscopic counting of parasites in 5 mL
of blood, as previously described [15]. Mortality was checked daily
until 30 dpi and expressed as percentage of survival.
Biochemistry. Blood was collected from the tip of mice tails
of all experimental groups at 15 dpi and immediately analyzed for
the determination of aspartate aminotransferase (AST), alanine
aminotransferase (ALT) and urea levels with Reflotron Plus
(Roche), according to the manufacturer recommendations. ALT
and AST activities were used to evaluate hepatic dysfunction and
the results were expressed as enzyme concentration (mg/dL). ALT
and AST belong to the group of transaminase that catalyses the
conversion of amino acids into corresponding a-ceto acids and
vice-versa by transference of amine groups. Urea was measured to
evaluate renal function and the results were expressed in
concentration (mg/dL).
Histopathology. Fixed tissue was dehydrated and embedded
in paraffin. Sections (3 mm) stained by routine haematoxylin-eosin
(HE) were analyzed by light microscopy. The number of
amastigote nests and of inflammatory infiltrates (more than 10
mononuclear cells), were determined in 30 microscopic fields/slide
(total magnification, 4006). The mean number of amastigotes or
inflammatory infiltrates per field was obtained at 15 dpi from at
Author Summary
Cardiac damage and dysfunction are prominent features in
patients with chronic Chagas disease, which is caused by
infection with the protozoan parasite Trypanosoma cruzi
(T. cruzi) and affects 10–12 million individuals in South and
Central America. Our group previously reported that
transforming growth factor beta (TGFß) is implicated in
several regulatory aspects of T. cruzi invasion and growth
and in host tissue fibrosis. In the present work, we
evaluated the therapeutic action of an oral inhibitor of
TGFß signaling (GW788388) administered during the acute
phase of experimental Chagas disease. GW788388 treat-
ment significantly reduced mortality and decreased para-
sitemia. Electrocardiography showed that GW788388
treatment was effective in protecting the cardiac conduc-
tion system, preserving gap junction plaque distribution
and avoiding the development of cardiac fibrosis. Inhibi-
tion of TGFß signaling in vivo appears to potently decrease
T. cruzi infection and to prevent heart damage in a
preclinical mouse model. This suggests that this class of
molecules may represent a new therapeutic tool for acute
and chronic Chagas disease that warrants further pre-
clinical exploration. Administration of TGFß inhibitors
during chronic infection in mouse models should be
further evaluated, and future clinical trials should be
envisaged.
GW788388 for Chagas Disease
www.plosntds.org 2 June 2012 | Volume 6 | Issue 6 | e1696Figure 1. GW788388 administration at 3 dpi decreased parasitemia and heart inflammatory infiltrates and increased survival rates.
Male Swiss mice were injected IP with 10
4 bloodstream trypomastigotes. Then GW788388 (3 mg/kg) or DMSO was administered by gavage at 3 dpi.
(A) Parasitemia was measured by direct counting of parasites in blood. (B) Percent survival was monitored during the experiment until 30 dpi. (C–F)
GW788388 for Chagas Disease
www.plosntds.org 3 June 2012 | Volume 6 | Issue 6 | e1696least three infected mice, with three sections per mouse per group.
The sections were observed using a Zeiss Axioplan microscope
(Zeiss, Oberkochen, Germany) coupled with Axiovision image
acquisition system (Zeiss). The area (%) of inflammatory infiltrates
was evaluated using NIH ImageJ software in at least 10 images per
group.
Histological assessment of cardiac fibrosis. Heart fibro-
sis was studied by (a) Masson’s trichrome staining at 15, 20 and
24 dpi as previously described [16], (b) immunohistochemical
staining of specific extracellular matrix proteins (collagen type I
and fibronectin, see below), and (c) Western blot analysis of
collagen type I and fibronectin protein levels (see below). For
collagen type I and fibronectin immunostainings, fixed tissue slides
were obtained as described above and heart fibrosis was studied by
collagen type I and fibronectin immunostainings at 15 dpi. Briefly,
after blocking with 3% BSA for 1 hour, the following primary
antibodies were applied overnight to the sections: rabbit polyclonal
anti-collagen type I (Novotec, France, kindly provided by Dr.
Daniella Areas Mendes-da-Cruz, IOC/Fiocruz) and rabbit
polyclonal anti-fibronectin (Sigma Aldrich, USA). The secondary
antibody was Alexa 594 goat anti-rabbit IgG (Invitrogen).
Negative control sections were incubated with non-immune rabbit
serum and the secondary antibody alone and indicated no cross
reactivity (data not shown). Host-cell nuclei were stained with 49,6-
diamidino-2-phenylindole dihydrochloride (DAPI). The sections
were observed using a Zeiss Axioplan microscope (Zeiss) coupled
with Axiovision image acquisition systems (Zeiss). Subsequent
automated analysis of the captured images (6–10 mice per group)
was carried out using an ImageJ macrobased algorithm that
identifies, separates and quantifies the light blue areas stained with
Masson’s trichrome representing fibrosis.
Cx43 plaque quantification. Cx43 staining on fixed tissue
was performed as described above. Briefly, heart sections were
blocked with 3% BSA for 1 hour, and incubated overnight with
rabbit polyclonal anti-connexin 43 (Sigma Aldrich, USA). The
secondary antibody was Alexa 488 goat anti-rabbit IgG (Invitro-
gen). Host-cell nuclei were stained with DAPI. The images were
obtained using a Zeiss Axioplan microscope at final magnification
of 6400. At this magnification, a typical test area included
approximately 34.600 mm
2 of tissue area. The images obtained in
each studied case were analyzed using the NIH software ImageJ to
determine the mean number and the length of Cx43 plaques by
quantification of 3-field images/animal.
Immunoblot analysis. Left ventricular heart proteins from
each group (NI, Y DMSO and Y GW788388) were extracted from
100 mg tissue/mL phosphate-buffered saline, to which 0.4 mol/L
sodium chloride, 0.05% Tween 20, and protease inhibitors
(0.1 mmol/L phenylmethylsulfonyl fluoride and 1/100 protease
inhibitors cocktail (Sigma)) were added. The samples were
sonicated twice and centrifuged for 10 min at 3000 g, and the
supernatant was kept frozen at 270uC. Proteins in the lysates
(20 mg/lane) were separated by SDS/PAGE and analyzed by
immunoblotting with specific primary antibodies (rabbit Anti-
fibronectin and rabbit Anti-connexin-43 from Sigma Aldrich and
rabbit Anti-collagen type I from Novotec, France). To confirm
equal protein loading, the same membranes were stripped and
reprobed with a monoclonal antibody against GAPDH (Pierce).
Electrocardiography (ECG). ECG recording and analysis
were performed in the three groups, as reported (30). Briefly, mice
were fixed in the supine position, and transducers were carefully
placed on the skin in accordance to chosen preferential derivation
(lead II). Traces were recorded using a digital system (Power Lab
2/20) connected to a bio-amplifier in 2 mV for 1 s (PanLab
Instruments). Filters were standardized between 0.1 and 100 Hz
and traces were analyzed using the Scope software for Windows
V3.6.10 (PanLab Instruments). ECG parameters were evaluated
in the acute phase at 15 dpi, using the following standard criteria:
(i) the heart rate, monitored by beats/minute (bpm), and (ii) the
variation at P wave and PR, QRS and QT intervals, all measured
in milliseconds (ms).
Statistical analysis. Differences were considered statistically
significant when p,0.05 (*) or p,0.01 (**), as determined by
GraphPadPrism 4.0 software (Graph- Pad Software Inc., San
Diego, CA, USA). The Kaplan- Meier test was used to analyze the
significances of the survival rates while all the other analyses were
performed using the non-parametric Mann–Whitney test.
Results
The aim of the present work was to evaluate whether the
compound GW788388, which is an ATP-competitive inhibitor of
the kinase activity of ALK5, could have a beneficial effect in vivo in
an experimental model of mouse acute infection by T. cruzi and
whether it could protect infected mice from parasite-induced
alterations of cardiac functions and fibrosis when administrated
early (3 dpi) and late (20 dpi).
Oral administration of GW788388 at 3 dpi reduced
parasitemia and heart damage and increased mice
survival rates in T. cruzi-infected mice
In the first set of experiments, the inhibitor GW788388 was
orally administered to male Swiss mice infected with 10
4
bloodstream trypomastigotes of the Y strain (day 0), at the 3rd
dpi. We first performed a dose-response study by administering
different doses of GW788388 (0.3, 3, 6 and 15 mg/kg) and
At 15 dpi, mice were sacrificed and heart sections stained with hematoxylin-eosin were analyzed by light microscopy. Numerous amastigote nests (C,
open arrows) and large inflammatory infiltrates (E, filled arrows) were observed in untreated T. cruzi-infected mice. GW788388 administration
decreased the number of amastigote nests (D, open arrow) and of inflammatory infiltrates (F). (G and H) The mean number of amastigote nests in 30
fields (G) and the area (%) of inflammatory infiltrates (more than 10 mononuclear cells) (H) are shown. Values for the infected group treated with
GW788388 that were significantly different from the value for the DMSO infected group are indicated (**p,0.01 and * p,0.05). n=10 mice/group in
4 independent experiments.
doi:10.1371/journal.pntd.0001696.g001
Table 1. Effect of GW788388 on the number of inflammatory
infiltrates in the heart at 15 dpi.
Number of cells per
Inflammatory
Infiltrates Y DMSO
Y
GW788388
Fold
decrease P value
Total 168645 94629 1.78 0.008
a
.50 29618 462 6.07 0.004
a
21–50 66619 24610 2.75 0.002
a
10–20 73628 65618 1.12 0.68
T. cruzi infected mice were treated with 3 mg/kg GW788388 at 3 dpi and the
number of inflammatory infiltrates in the heart was counted at 15 dpi.
aSignificant differences (p,0.01) between the values for infected non treated (Y
DMSO) and treated (Y GW788388) groups of mice.
doi:10.1371/journal.pntd.0001696.t001
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www.plosntds.org 4 June 2012 | Volume 6 | Issue 6 | e1696Figure 2. GW788388 administration at 3 dpi decreased liver and renal alterations. Male Swiss mice were injected IP with or without (NI)
10
4 bloodstream trypomastigotes. Then GW788388 (3 mg/kg) or DMSO was administered by gavage at 3 dpi. (A and B) At 15 dpi mice were
sacrificed, and liver sections stained with hematoxylin-eosin were analyzed by light microscopy. Large inflammatory infiltrates (A, white arrow) were
observed in untreated T. cruzi-infected mice. (C) The mean number of inflammatory infiltrates (more than 10 mononuclear cells) in 30 fields is shown.
(D and E) The serum levels of AST and ALT, two markers of hepatic lesion, were measured at 15 dpi. (F) The serum urea levels were measured to
evaluate renal function. Each symbol shows the value for one mouse. The short black bars show the mean value for each group. Values that were
significantly different from studied groups are indicated by asterisks (**p,0.01 and * p,0.05). n=3 mice/group in 3 independent experiments.
doi:10.1371/journal.pntd.0001696.g002
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dependent inhibition of parasitemia at 8 dpi from 0.3 to 15 mg/kg
of GW788388 (Methods S1 and Fig. S1A). On the other hand, the
survival rate was increased with 3 or 6 mg/kg of GW788388 but
unaltered at 0.3 and 15 mg/kg, suggesting some toxicity of the
drug at this largest dose (Fig. S1B). For the subsequent studies, the
dose of 3 mg/kg was chosen since it was the lowest GW788388
concentration that significantly affected parasitemia without
worsening mortality. The choice for 3 mg/kg GW788388
administration was further reinforced by the assays performed
by Gellibert and collaborators [13], who showed in a model of
kidney fibrosis that doses as low as 3 mg/kg/mice of GW788388
significantly inhibited collagen type I mRNA levels. The control
group received the vehicle buffer in which GW788388 was diluted
(4% DMSO, 96% [0.5% Hydroxypropylmethylcellulose (HPMC),
5% Tween 20, 20% HCl 1 M in NaH2PO4 0.1 M]) and could be
considered as the placebo group. The responses of DMSO-treated
infected mice were not significantly different from those of
untreated infected mice, excluding any sham or placebo effect
(data not shown). In our model of acute infection, as previously
described [12], parasitemia peaked at 8 dpi (Fig. 1A). We found
that GW788388 administration at 3 dpi significantly reduced the
blood parasitemia peak (Fig. 1A). Further, as previously described
with the compound SB421543 [11], we could demonstrate that in
vitro administration of GW788388 on cardiomyocytes impaired T.
cruzi replication in host cells (Fig. S2) supporting the decreased
parasitemia peak found in vivo. On the other hand, no effect of
GW788388 on trypomastigote forms of T. cruzi viability could be
observed after direct incubation of the drug with the parasites
(unpublished result). We also showed that GW788388 adminis-
tration significantly increased survival rates at 30 dpi (65% in the
treated-group versus 34% in the untreated group, Fig. 1B). The
infection induced a loss of body weight at 14 dpi [12], which was
not modified by the administration of GW788388 (data not
shown). To investigate whether GW788388 treatment would also
affect myocardial parasitism and infiltration of inflammatory cells,
we analyzed mouse infected heart sections collected at 15 dpi
using histochemical techniques. Non-infected animals showed no
inflammatory infiltration in the myocardium (data not shown).
Myocardial sections from the T. cruzi-infected sham-treated group
(Y DMSO) had many amastigote nests (Fig. 1C, open arrows) and
Figure 3. GW788388 administration at 3 dpi restored Electrocardiographic parameters. Male Swiss mice were injected IP with or without
(NI) 10
4 bloodstream trypomastigotes. Then GW788388 (3 mg/kg) (Y GW788388) or DMSO (Y DMSO) was administered by gavage at 3 dpi.
Representative electrocardiographic tracings of the three groups at 15 dpi are shown. n=6 mice/group in 3 independent experiments.
doi:10.1371/journal.pntd.0001696.g003
Table 2. Effect of GW788388 on electrocardiograph
parameters at 15 dpi.
ECG parameters (Mean
± SD) Non-infected Y + DMSO Y + GW788388
Heart rate (bpm) 774.2630.6 495.8679.2
a 554.3644.5
c
PR intervals (ms) 28.663.1 50.468.2
a 45.168.4
QRS intervals (ms) 8.661.4 10.662.7
b 9.762.0
QT intervals (ms) 22.868.9 29.665.5
b 25.366.4
c
Frequency of AVB1 0/10 (0%) 15/18 (83%) 5/18 (28%)
Frequency of AVB2 0/10 (0%) 13/18 (72%) 6/18 (33%)
ECG parameters were evaluated in the acute phase at 15 dpi, using the
following standard criteria: (i) the heart rate was monitored by beats/minute
(bpm), and (ii) the variation at P wave and PR, QRS and QT intervals, all
measured in milliseconds (ms). The incidence of AVB1, atrioventricular block
type 1 and AVB2, atrioventricular block type 2 are stated in absolute numbers
and in percentage. Significant differences between the values for non-infected
and infected groups of mice:
a(p,0.01) and.
b(p,0.05).
cSignificant differences (p,0.05) between the values for infected non treated (Y
DMSO) and treated (Y GW788388) groups of mice.
doi:10.1371/journal.pntd.0001696.t002
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www.plosntds.org 6 June 2012 | Volume 6 | Issue 6 | e1696Figure 4. GW788388 administration at 3 dpi inhibited connexin 43 disruption. Male Swiss mice were injected IP with or without (NI) 10
4
bloodstream trypomastigotes. Then GW788388 (3 mg/kg) (Y GW788388) or DMSO (Y DMSO) was administered by gavage at 3 dpi. (A–C) At 15 dpi,
mice were sacrificed and heart sections stained with anti-Cx43 antibody (green, Cx43 plaques are indicated by white arrows) and DAPI (nuclei,
colored in blue). Quantitative analysis of the number of Cx43 plaques (D) and length (E), on images from each group studied (NI, Y DMSO and Y
GW788388). Values are expressed as the mean6SD (F) 20 mg of total proteins from hearts at 15 dpi were resolved in 12% SDS/PAGE and
immunoblotted with anti-Cx43 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies. (G) Densitometric histograms of the
normalized levels of Cx43 as related to GAPDH are shown. Values that were significantly different from studied groups are indicated by asterisks
(* p,0.05). n=3 mice/group in 3 independent experiments.
doi:10.1371/journal.pntd.0001696.g004
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www.plosntds.org 7 June 2012 | Volume 6 | Issue 6 | e1696Figure 5. GW788388 administration at 3 dpi decreased heart fibrosis. Male Swiss mice were injected IP with or without (NI) 10
4 bloodstream
trypomastigotes. Then GW788388 (3 mg/kg) (Y GW788388) or DMSO (Y DMSO) was administered by gavage at 3 dpi. At 15 dpi, mice were sacrificed
and heart sections stained with anti-collagen type I antibody (A and B, open arrow) or anti-fibronectin antibody (C and D, white arrow) colored in red
and DAPI (nuclei, colored in blue). (E) 20 mg of total proteins from hearts at 15 dpi were resolved in 12% SDS/PAGE and immunoblotted with anti-
GW788388 for Chagas Disease
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associated with fibrotic areas. GW788388 treatment significantly
decreased the number of amastigote nests (Fig. 1D and 1G).
GW788388 administration also significantly decreased the area
invaded by inflammatory infiltrates (Fig. 1F and 1H). A more
detailed count of the number of cells per inflammatory foci showed
that GW788388 treatment more particularly decreased the
number of large inflammatory foci within the myocardium (larger
than 20 or 50 cells per inflammatory infiltrates) (Table 1).
GW788388 controlled liver alteration caused by acute
experimental T. cruzi infection
T. cruzi infection induces a strong hepatitis during the acute
phase of Chagas disease [17]. We therefore analyzed several
parameters of the liver in sham-treated versus GW788388-treated
mice. Analysis of liver sections at 15 dpi revealed the presence of
large inflammatory infiltrates in DMSO-treated animals (Fig. 2A,
arrow). GW788388 administration significantly decreased the
number of these infiltrates (Fig. 2B and C). We also measured two
circulating markers of hepatic function which are induced by T.
cruzi infection: AST (aspartate aminotransferase) and ALT (alanine
aminotransferase). We found that GW788388 administration
significantly decreased the serum levels of AST and ALT
(Fig. 2D and E). We also measured urea, which reflects the renal
functional status. Urea level was significantly increased at 15 dpi in
DMSO-treated animals while GW788388 administration signifi-
cantly reduced it (Fig. 2F).
GW788388 prevented heart damage from T. cruzi
infection
We next analyzed electrocardiograms (ECG) of the different
groups of mice at 15 dpi. As expected, analysis of the ECG
demonstrated an atrial ventricular block with PR interval higher
than 40 ms, leading to sinus bradycardia in sham-treated T. cruzi-
infected animals as compared to the non-infected control group
(495.8 and 774.2 bpm, respectively, Figure 3 and Table 2).
GW788388 administration significantly limited the bpm decrease
at 15 dpi, with a mean heart rate of 554.3 (Fig. 3 and Table 2).
The other parameters analyzed demonstrated that infected mice
had higher QT, PR and QRS intervals compared to non-infected
mice (Table 2), and that GW788388 administration (3 mg/kg) also
significantly decreased the QT intervals to 25.3 ms as compared to
29.6 in the infected DMSO-treated group (Table 2). A possible
cause of this worsening in heart electrical conduction after the
infection could be the direct effect of TGFß in heart cells. It has
been already proposed that elevated TGFß levels during T. cruzi
infection disorganize gap junctions, possibly contributing to
abnormal impulse conduction and arrhythmia in Chagas disease
[12]. To test this hypothesis, we measured connexin 43 (Cx43)
expression in the different groups of mice. Heart sections from at
least three mice per group at 15 dpi were immunostained for
Cx43. We observed by confocal microscopy that non-infected
hearts presented a dense structure of gap junction plaques (Fig. 4A,
green staining). A drastic change in Cx43 expression was observed
in the infected hearts of vehicle-treated mice, with an important
decrease in Cx43 expression and a disruption of gap junction
plaques (Fig. 4B). We found that GW788388 treatment reduced
Cx43 disassembly and prevented the dissolution of gap junctions,
preserving organized plaque distribution (Fig. 4C). The mean
number of Cx43 plaques and their mean length were significantly
lower in the heart of infected mice at 15 dpi as compared to the
non-infected group (Fig. 4D and E). GW788388 treatment
protected infected-mice from this loss as the decrease in the mean
number of plaques was only reduced by 30% versus 45% in non-
treated mice (Fig. 4D) and the mean length was similar to the non-
infected mice (Fig. 4E). Immunoblotting analysis of Cx43
expression from heart ventricles confirmed these data (Fig. 4F
and G).
GW788388 prevented heart fibrosis development in T.
cruzi-infected mice
One of the best established biological function of TGFß is the
stimulation of extracellular matrix (ECM) protein deposition.
Therefore, we checked whether GW788388 treatment would
affect heart fibrosis that occurs in response to T. cruzi infection.
Left ventricular heart tissues were obtained from each group and
the deposition of ECM proteins was studied by immunostaining
for collagen type I and fibronectin at 15 dpi. We observed an
interstitial fibrous heart with high levels of both collagen type I and
fibronectin deposition, as observed in red on Figure 5A and C,
respectively. Interestingly, we could show that oral administration
of GW788388 significantly reduced collagen type I and fibronectin
levels (Fig. 5B and D, respectively). These data were confirmed by
immunoblotting analysis of collagen type I and fibronectin
expression from heart ventricles (Fig. 5E, F and G).
We found that GW788388-treatment decreased the phosphor-
ylation level of Smad2 in infected hearts, demonstrating that
GW788388-treatment was related to TGFß dependent signaling
in vivo (data not shown).
Oral administration of GW788388 at 20 dpi also
increased mice survival rates and reduced heart fibrosis
in T. cruzi infected mice
Because most of the beneficial effects that we observed here with
the TGFß inhibitor (GW788388) might be due to the resulting
decreased parasitemia due to the inhibitory effect of TGFß
signaling inhibitors in host cell invasion and intracellular
proliferation [11,12], we next studied the effect of GW788388
oral administration after the parasitemia peak. We chose to add
GW788388 at 20 dpi as by this time, only 18% of infected mice
survived and 30% of them died at 24 dpi. Interestingly, we found
that GW788388 administration at 20 dpi completely protected
these mice (n=12) from death until 24 dpi (Fig. 6A, inset). In the
inset, 100 represents the percentage of survival rate calculated
from 20 dpi. GW788388 administration still decreased the
number of inflammatory infiltrates within the myocardium
(Table 3). To verify if GW788388 treatment presented an effect
in the reversion of installed fibrosis, we performed Masson’s
trichrome staining on heart cross-sections of infected untreated
mice at 15 dpi (Fig. 6B), 20 dpi (Fig. 6C) and 24 dpi (Fig. 6D), and
of infected GW788388-treated mice at 24 dpi (Fig. 6E). We
observed a progressive increase in collagen deposition visualized as
light blue staining, which followed fibrosis progression (from 15 to
24 dpi, Table 4). At 20 dpi, which corresponded to the day of
GW788388 administration, we observed a fibrotic pattern on the
heart of infected mice frequently associated to inflammatory
fibronectin or anti-collagen type I antibodies and reprobed with anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody. (F and G)
Densitometric histograms of the normalized levels of fibronectin or collagen type I as related to GAPDH are shown. Values that were significantly
different from studied groups are indicated by asterisks (**p,0.01 and * p,0.05). n=3 mice/group in 3 independent experiments.
doi:10.1371/journal.pntd.0001696.g005
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www.plosntds.org 9 June 2012 | Volume 6 | Issue 6 | e1696Figure 6. GW788388 administration at 20 dpi protected T. cruzi-infected mice from death and decreased heart fibrosis. Male Swiss
mice were injected IP with or without (NI) 10
4 bloodstream trypomastigotes. Then GW788388 (3 mg/kg) (Y GW788388) or DMSO (Y DMSO) was
administered by gavage at 20 dpi. (A) Percent survival was monitored during the experiment until 24 dpi (Inset shows a blow-up of the survival curve
from 20 to 24 dpi (100 represents the percentage of survival calculated from 20 dpi)). (B, C, D, E) Untreated infected mice were sacrificed at 15 dpi (B),
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www.plosntds.org 10 June 2012 | Volume 6 | Issue 6 | e1696infiltrates (Fig. 6C). Interestingly, four days after GW788388
administration (i.e. 24 dpi) we observed a decrease in collagen
deposition (Fig. 6E) as compared to the untreated group (Fig. 6D,
Table 4). Immunoblotting assays were performed to compare the
expression levels of collagen type I between each group. We
observed a significant increase in collagen type I expression in the
DMSO infected group as compared to the non-infected group
(Fig. 6F and G, 9 fold increase), while GW788388 administration
to infected mice significantly decreased the expression levels of
collagen type I (Fig. 6F and G).
Discussion
We have recently demonstrated that in vivo inhibition of the
TGFß signaling pathway can decrease infection and prevent heart
damage [12], suggesting that this new class of therapeutic agents
should be considered in association with trypanocidal compounds
for the potential treatment of Chagas disease cardiomyopathy. In
the present work, we demonstrated that a more potent inhibitor of
the TGFß signaling pathway, GW788388, which can be orally
administered, significantly decreased parasitemia, increased sur-
vival and restored cardiac function as measured by ECG heart
frequency (increase in bmp) and atrial conduction (decrease in QT
interval). When administered at 3 dpi, we observed that
GW788388 treatment reduced parasitemia and its subsequent
deleterious effects. Whether the protective effect of GW788388
results only from this sole anti-infectious effect remains to be
established. However, the short half-life of GW788388 in vivo
(plasma T1/2=1.3 hours; [13]) makes it unlikely that it is
mediated by long-term effects on e.g. fibrosis or cardiac rhythm.
In contrast, administration of GW788388 at 20 dpi to mice that
survived the metabolic distress syndrome clearly resulted in
improved survival, which correlated with decreased cardiac
fibrosis and has probably no causal relationship with the anti-
infectious effect of the drug. Given the recent availability of
reliable mouse models for chronic chagasic cardiomyopathy [18],
the present proof that orally administrated GW788388 is feasible
and efficient in the acute phase will offer in the near future the
possibility of testing TGFß inhibitors in the chronic phase in pre-
clinical assays. Taken together, these data further support that
blocking TGFß signaling could represent a potential new
therapeutic approach for Chagas disease heart fibrosis treatment.
It is now well established that the involvement of the TGFß
signaling pathway plays an important role in the development of
Chagas disease [8]. TGFß has been shown to be involved during
parasite-host cell invasion, proliferation and differentiation [19–
22]. Moreover, significantly higher circulating levels of TGFß1
have been observed in patients with Chagas disease cardiomyop-
athy [9,16]. These data incited us to test the possibility of treating
the development of Chagas disease by blocking the TGFß
signaling pathway.
Here, we show that oral administration of GW788388 kinase
signaling inhibitor prevents parasitemia, mortality, and heart
fibrosis to acutely T. cruzi-infected mice in comparison to
untreated-infected experimental group of animals. In lack of
demonstration of GW788388 direct killing effect upon T. cruzi,w e
postulate the protein kinase inhibitor used may induce intracellular
parasite latency [23,24], such as that involved with the Plasmo-
dium sporozoites cell cycle inhibition of initiation factor-2alpha
(elF2alpha) kinase (IK2); its down-regulation by removal of PO4
from elF2alpha-P gives rise to the latency [25,26]. In this regard,
ongoing investigations in chronically T. cruzi-infected mouse
model will determine whether GW788388 beneficial effects can
be explained by the drug-induced parasite latency and long lasting
cryptic infections.
Several approaches have been developed to abrogate TGFß
signaling. Antibodies directed against TGFß have been adminis-
tered in diabetic rodents and this was shown to efficiently prevent
20 dpi (C), 24 dpi (D) and GW788388-treated mice at 20 dpi were sacrificed at 24 dpi (E). Heart sections were stained for collagen deposition by
Masson’s trichrome (light blue staining, open arrows). (F) 20 mg of total proteins from hearts at 24 dpi were resolved in 12% SDS/PAGE and
immunoblotted with anti-collagen type I antibody and reprobed with anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody. (G)
Densitometric histograms of the normalized levels of collagen type I as related to GAPDH are shown. Values that were significantly different from
studied groups are indicated by asterisks (**p,0.01 and * p,0.05). n=4 mice/group in 3 independent experiments.
doi:10.1371/journal.pntd.0001696.g006
Table 3. Effect of GW788388 on the number of inflammatory
infiltrates in the heart at 24 dpi.
Number of cells
per Inflammatory
Infiltrates Y DMSO
Y
GW788388
Fold
decrease P value
10–20 40642 7 65 1.5 0.02
a
21–50 14669 64 1.5 0.3
.50 11672 61 4.3 0.1
Total 66618 3965 1.7 0.1
T. cruzi infected mice were treated with 3 mg/kg GW788388 at 20 dpi and the
number of inflammatory infiltrates in the heart was counted at 24 dpi.
aSignificant differences (p,0.05) between the values for infected non treated (Y
DMSO) and treated (Y GW788388) groups of mice.
doi:10.1371/journal.pntd.0001696.t003
Table 4. Effect of GW788388 on the fibrosis scores of the
heart at 20 dpi.
dpi 15
DMSO
dpi 20
DMSO
dpi 24
DMSO
dpi 24
GW788388
Number of mice 7 8 10 6
% area stained for Masson’
Trichrome
25.7 33.8 55.8 4.8
23.9 18.8 35.7 6.2
22.6 14.4 30.0 3.1
5.2 53.8 7.7 2.9
56.1 55.9 8.2 2.9
5.1 13.2 13.7 8.3
nd 39.4 54.0
16.1 54.0
20.2
9.2
Mean 6 SD 23.1618.6 30.7617.6 28.9620.0 4.762.2**
T. cruzi infected mice were treated with 3 mg/kg GW788388 at 20 dpi and
fibrosis was quantified before (15 and 20 dpi) and after (24 dpi) treatment.
Percent of Masson’s Trichrome stained area (light blue areas) were quantified
using NIH ImageJ Software in the microscopic images of heart sections.
**Significant differences (p,0.01) between the values for Y DMSO and Y
GW788388 groups of mice observed at 24 dpi. nd: not detected.
doi:10.1371/journal.pntd.0001696.t004
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oligonucleotides were found to reduce kidney weight in diabetic
mice [28]. Recently, a soluble fusion protein of TßRII was
reported to reduce albuminuria in a chemically induced model of
diabetic nephropathy in rats [29]. And finally, inhibitors of the
kinase activity of the TßRI (ALK5) have been developed. These
inhibitors interact with the ALK5 ATP-binding site, thereby
preventing TGFß intracellular pathways [30]. The first ALK5
inhibitor described, SB431542, is an ATP-competitive kinase
inhibitor [31]. SB431542 significantly reduced procollagen1alpha
(I) in rat kidneys in a model of induced nephritis. It was also
described that SB431542 triggers antitumor activity in vivo [32].
Our work also demonstrated that SB431542 reduced mortality,
decreased parasitemia and prevented heart damage as observed by
histological and ECG analysis during the acute phase of
experimental Chagas disease [12]. However, the limitations of
SB431542 were the need of intraperitoneal injection and the in vivo
toxic effects that have been demonstrated. Recently, GW788388
was developed as an alternative to SB431542 with better in vivo
exposure. GW788388 is orally active and has a good pharmaco-
kinetic profile [13,14,30]. GW788388 administration reduced liver
and renal fibrotic response in a model of chemically induced
fibrosis in rats and in the db/db mouse model of spontaneous
diabetic nephropathy [13,14]. Treatment with GW788388 also
showed efficacy for preventing the fibrotic response in a skin
fibrosis model [33] and attenuated cardiac dysfunction following
myocardial infarction [34]. These data prompted us to test this
compound during the acute phase of experimental Chagas disease.
We found that oral administration of GW788388 at 3 dpi
significantly reduced peripheral parasitemia and lowered parasite
load in hearts of infected mice observed 15 dpi. This effect was
achieved with lower administration doses (3 mg/kg) than the one
we previously used for SB431542 (10 mg/kg) [12], and with a
single oral administration. More importantly, oral administration
of GW788388 also significantly improved mice survival (70% in
GW788388-treated mice against 30% in non-treated infected mice
at 30 dpi). This is probably due to the combined impairment of
the second wave of T. cruzi parasitemia due the decrease of
parasite burden and of the early inflammatory cytokines secretion
balance. Infection with T. cruzi in the acute phase is followed by a
strong mononuclear cell inflammation on target tissues such as
heart and liver, which could cause tissue disruption, necrosis
followed by fibrotic deposition and abnormalities in electrical
impulse conduction. Our data showed less inflammation on both
heart and liver tissues and, moreover, less mononuclear cells by
inflammatory focus. An improved ECG profile was also observed
after GW788388 administration, characterized mainly by the
absence of sinus node dysfunctions and reduced sinus bradycardia.
PR intervals larger than 40 ms suggested slower transmission of
the electrical impulses and atrioventricular block (AVB), which is
characteristic of acute T. cruzi infection [35]. We observed an
improvement of the QT intervals following GW788388 adminis-
tration, which represent the wave of ventricular recuperation and
this could be related to the decrease of sudden death [36] and to
the progression to a pathological chronic phase [35]. Heart failure
and sudden death are the most common causes of death in patients
with chronic cardiac Chagas disease [37] and altered ECG
parameters correlates with increasing myocardial scar and
decreasing myocardial function in these patients [38]. This results
from disorganized gap junctions that could contribute to abnormal
impulse conduction and arrhythmia that characterize severe
cardiopathy in Chagas disease and heart fibrosis [10]. Gap
junction Cx43 molecules are responsible for electrical impulse
conduction in the heart [39] and are affected by TGFß [10,40].
We observed that GW788388 treatment preserved a correct Cx43
plaque pattern in the heart and blocked the down-regulation of
Cx43 expression commonly observed following T. cruzi infection.
GW788388 treatment therefore favored a regular and correct
electrical impulse transmission. TGFß is also a key factor in the
generation of tissue fibrosis [41] and has been correlated to
development of Chagas disease symptoms in cardiac chronic phase
[8]. Our data showed that administration of GW788388 to T.
cruzi-infected mice significantly prevented the increase of fibro-
nectin and collagen type I, two important components involved in
heart fibrosis. These data are consistent with previous studies
showing that GW788388 reduced fibrosis markers in the kidney
following chemically induced nephropathy [14,42].
In the human acute phase of Chagas disease, symptoms are
frequently mild and not noticed and it is therefore difficult to
propose correct treatments with trypanocidal drugs. Therefore, in
the present study, we also treated mice with GW788388 at the end
of the acute phase, when there are scarce circulating parasites.
Interestingly, we found that oral administration of GW788388 at
20 dpi completely protected mice from death (100% survival).
Analysis of cardiac fibrosis by Masson’s trichrome staining on
heart cross-sections of T. cruzi-infected mice showed a strong
increase of fibrosis from 15 dpi to 24 dpi (Fig. 5, Table 4).
Interestingly, we found that mice treated with GW788388, in a
single dose scheme at 20 dpi, reversed heart fibrosis observed four
days later (24 dpi) as compared to untreated infected mice. The
level of collagen type I was also restored in GW788388 treated
mice versus untreated mice. Taken together these data demon-
strated that blocking TGFß signaling could decrease an installed
heart fibrosis. This important finding encourages further pre-
clinical assays targeting fibrotic lesions that are always involved in
the severity of the clinical picture observed in the chronic cardiac
disease. The development of an efficient drug for Chagas disease is
still a challenge and trypanocidal drugs such as nifurtimox and
benznidazole are still the only drugs employed for specific Chagas
disease treatment, although the observation of serious side effects.
Treatment strategy approaching the reversion of fibrosis has been
demonstrated here at the end of the acute phase of experimental
Chagas disease. Still, further studies on a chronic experimental
model are necessary previously to clinical assays. The inhibition of
TGFß signaling pathway and its biological functions could then be
considered as an alternative strategy for the treatment of the
symptomatic cardiomyopathy found in the acute and chronic
phases of Chagas disease, in synergy with current administered
drugs, enabling lower dosages and avoiding toxic effects.
Supporting Information
Figure S1 Dose-dependent analysis of the effect of oral
administration of GW788388 at 3 dpi on parasitemia
and survival rates. Male Swiss mice were injected ip. with 10
4
bloodstream trypomastigotes. Then GW788388 (0.3–15 mg/kg)
or vehicle (DMSO) was administered once by gavage at 3 dpi. (A)
Parasitemia was measured by direct counting of parasites in blood.
(B) Percent survival was monitored until 30 dpi.
(EPS)
Figure S2 Effects of in vitro GW788388 administration
to cardiomyocytes on T. cruzi invasion and replication.
Cardiomyocytes were infected with trypomastigotes of the Y strain
in a parasite:host cell proportion of 10:1 and 24 h post- infection,
cultures were treated or not with GW788388 (10 mM). Cells were
fixed 48 h (A and B) and 96 h (C and D) post-infection and stained
with Giemsa. Magnification: 4006. Quantification of the
percentage of cardiomyocytes containing parasites (E) and the
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www.plosntds.org 12 June 2012 | Volume 6 | Issue 6 | e1696number of parasites per infected cell (F) were determined by
counting 400 cells/slide on two distinct coverslips at 48 and 96 h
post-infection.
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Methods S1 GW 788388 dose-response effect in vivo.
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